EClinicalMedicine 42:101213 Yeh TL et al (2023) Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: a multivariate meta-analysis
While liraglutide also showed cardiovascular benefit (13% reduction in the LEADER trial), semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity
This naturally occurring compound plays a crucial role in converting fat into energy, which is why its often marketed as a metabolism booster
Retatrutide versus semaglutide and retatrutide versus tirzepatide (Mounjaro) comparisons can help you evaluate whether a dual or single agonist might achieve acceptable results with fewer neurological side effects
Cell 175(3):887888 Garfield AS, Heisler LK (2009) Pharmacological targeting of the serotonergic system for the treatment of obesity
Inflammatory bowel conditions, leaky gut syndrome, and other gastrointestinal issues may respond to BPC-157's protective and healing effects